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1. Introduction 
Since the outbreak of the novel coronavirus disease 2019 
in December 2019, throughout the Hubei province of 
China, several clinical trials have been conducted to assess 
the benefits of certain therapies. Tocilizumab, also known 
as atlizumab, is an immunosuppressive drug, mainly 
for the treatment of rheumatoid arthritis and systemic 
juvenile idiopathic arthritis, a severe form of arthritis in 
children. It is a humanized monoclonal antibody against 
the interleukin-6 receptor. Although every observational 
study of COVID 19 so far has hinted at the benefits of 
drugs that may block inflammatory cytokines, trials of 
interleukin 6 inhibitors, such as sarilumab, have yet to 
show any viable benefits [1].  As of 13th October 2020, 1.08 
million individuals have died due to coronavirus disease 
2019 (COVID-19), with 37.6 million cases documented 
worldwide. While the death toll reaching over 1 million 
individuals worldwide, the results of randomized, double-
blind, placebo-controlled trials have raised questions about 
the benefits or tocilizumab in patients with COVID-19 [2]. 
The World Health Organization (WHO) estimates 
that the mortality rate of disease caused by COVID-19 is 
3.7%, which is 10 times higher than that seen in influenza 
[3]. Afflicted patients may have an overwhelming immune 
reaction causing the cytokine storm syndrome with 
elements of the Macrophage Activation Syndrome (MAS), 
Cytokine-Release Syndrome (CRS), leading to Acute 
Respiratory Distress Syndrome (ARDS). SARS-CoV-2 leads 
to the production of inflammatory cytokines including 
Interleukin-6, which then contributes to cytokine storm 
syndromes damaging the lungs and other organs, ultimately 
leading to death. IL-6 is a pleiotropic proinflammatory 
cytokine produced by many cell types including fibroblasts, 
monocytes, and lymphocytes. The SARS-CoV-2 infection 
leads to a dose-based production of IL-6 from bronchial 
cells [4]. Interleukin inhibitors may help ameliorate severe 
damage to the lung tissue caused by cytokine release in 
patients infected with severe COVID-19 disease.
As of September 2020, there are 280  COVID-19 
clinical trials registered for the treatment of COVID-19 
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in clinicaltrials.gov. The clinical course and mortality 
outcomes have baffled the population and healthcare 
organizations due to the heterogeneity in clinical 
presentations with some being asymptomatic to others 
acquiring severe pneumonia with respiratory failure 
leading to mechanical ventilation or death [5]. 
While the National Institute of Health guidelines 
proposed that insufficient data were present to support the 
use of interleukin-6 inhibitors other than for COVID-19 
clinical trials, until more concrete evidence is available, 
healthcare providers must exercise caution in prescribing 
immune-modulating therapies [6]. This meta-analysis 
reviews the benefits of Tocilizumab for severe COVID-19 
patients and critiques the methodologies of ongoing 
clinical trials.
2. Materials and methods
2.1. Search strategy 
All potential studies were identified by conducting a 
systematic search using PRISMA guidelines. Two databases 
were searched to include observational studies including 
PubMed (MEDLINE) and Cochrane Central. Additional 
studies were located using medRxiv and bioRxiv, in 
addition to grey literature sources, such as the WHO-
COVID database and Google Scholar. A combination of 
keywords was used including “Tocilizumab,” “Actemra”, 
and “COVID-19.” An additional search was conducted on 
Clinicaltrials.gov to locate all ongoing tocilizumab trials.
2.2. Inclusion and exclusion criteria 
All studies comparing the clinical benefits and all-cause 
mortality outcomes of tocilizumab were included in the 
study. The comparators for the treatment for COVID-19 
named as controls in our study were receiving standard 
treatment of care or no treatment.  Articles published 
after January 1st, 2020, were included with no language 
restrictions. We excluded 1) case studies, 2) case series, 
3) letter to editors, 4) single-arm studies, and 5) two-arm 
studies that did not report any outcomes of interest.1 
6. National Institutes of Health (2020). COVID-19 
Treatment Guidelines Panel. Therapeutic Options Under 
Investigation, Coronavirus Disease COVID-19 [online]. 
Website https://www.covid19treatmentguidelines.nih.
gov/ [accessed 20 September 2020].
Two early-to-mid level researchers (ZS and AS) 
searched the articles independently. All discrepancies 
were resolved by the third author (MA). Data were 
systematically collected for the primary outcome, which 
was mortality in both treatment and control group, and the 
secondary outcome, mechanical ventilation using a shared 
spreadsheet for the meta-analysis. For all ongoing clinical 
1 National Institutes of Health (2020). COVID-19 Treatment Guidelines Panel. Therapeutic Options Under Investigation, Coronavirus Disease COV-
ID-19 [online]. Website https://www.covid19treatmentguidelines.nih.gov/ [accessed 20 September 2020].
trial registrations, findings were tabulated as 1) clinical 
trial identifier, 2) study design, 3) estimated enrollment, 
4) conditions, 5) phase of the study, 6) interventions 
(experimental vs. comparator), 7) primary outcome 
measure and 8) recruitment status.
2.3. Objectives
The primary objective was to determine whether 
tocilizumab reduced the risk of mortality in the treatment 
groups. The secondary objective was to identify if the risk 
of mechanical ventilation was higher in either group. 
2.4. Data analysis 
All analyses were carried using Review Manager V5.4. The 
Mantel–Haenszel random-effects model was used with 
95% confidence intervals. A test of P ≤ 0.05 was considered 
significant. A presentation of the Unadjusted Odds ratios 
(ORs) was given for dichotomous variables (I. mortality 
and II. mechanical ventilation). The I2 index was identified 
to assess heterogeneity among the included studies. A 
funnel plot was generated for visual inspection if more 
than 10 studies were included in either analysis. The study 
was not registered in an online register due to the time-
sensitivity of the topic.  
3. Results
We included 13 studies in the meta-analysis [5,7–17]. There 
were a total of 2120 patients, with 674 (31.8%) patients in 
the tocilizumab group and 1446 (68.2%) patients in the 
control group. Our results indicate that patients treated 
with tocilizumab had lower risks of mortality as compared 
to those who received no treatment or standard COVID-19 
therapies (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005). 
There was moderate heterogeneity in included studies (I2 = 
55%) (Figure 1), whereas, the risk of mechanical ventilation 
was inconclusive in those who obtained tocilizumab 
therapy (OR = 0.95, 95% CI = 0.53 to 1.72, P = 0.88, I2 
= 61%) (Figure 2). The included studies provide clear 
evidence that the treatment group has a lower risk of death 
in severe COVID-19 patients, requiring further proof in 
the form of randomized controlled trials. However, the 
findings do not identify a clear demarcation of risks of 
mechanical ventilation between the treatment and control 
groups. Publication bias was noted within acceptable 
limits and high to moderate level methodological studies 
were included in our analysis (Figure 3).
Using the keywords “COVID-19” and “tocilizumab,” 
a total of 67 studies were located on Clinicaltrials.gov, 
of which we present a total of 50 registered trails. Of all, 
we included 4(8%) nonrandomized, open-label studies, 
7(14%) randomized, double-masked (participant and 
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Figure 1. Mortality associations between the tocilizumab group and the control group.
Figure 2. Odds of mechanical ventilation between the tocilizumab group and the control group.
Figure 3. Funnel plot showing publication bias of included studies. Each dot represents a single study. The X axis shows the result of the 
study expressed as an odds ratio for mortality in tocilizumab and control groups. The Y axis is the standard error of the effect estimate. 
The shape is asymmetrical as it does not resemble that of an inverted funnel or a pyramid representing publication bias. Given that the 
I2 value was 55%, study heterogeneity may have led to an asymmetrical funnel.
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Interventions Primary outcome measures
Recruitment 
status
1 NCT04331795 Nonrandomized, open label 32 Phase 2 Tocilizumab Clinical response Completed
2 NCT04339712 Nonrandomized, open label 40 Phase 2 Anakinra, Tocilizumab
Change of baseline total sequential organ failure 
assessment (SOFA) score|
Recruiting
3 NCT04492501 Nonrandomized, open label 600 Not Applicable
Therapeutic plasma exchange, convalescent plasma,  










masking between participant 
and investigator
72 Phase 3 Methylprednisolone vs. Placebo
Proportion of patients developing treatment 




masking between participant 
and investigator
300 Phase 3 Tocilizumab vs. Placebo





masking between participant 
and investigator
243 Phase 3 Tocilizumab vs. Placebo
The time from administration of the 
investigational agent (or placebo) to requiring 
mechanical ventilation and intubation, or death 





masking between participant 
and investigator
379 Phase 3 Tocilizumab vs. Placebo
Cumulative Proportion of Participants





masking between participant 
and investigator
450 Phase 3 Tocilizumab vs. Placebo





masking between participant 
and investigator
450 Phase 3 Remdesivir, Tocilizumab vs. Placebo
Clinical Status as Assessed by the Investigator 
Using a 7-Category Ordinal Scale of Clinical 




masking between participant 
and investigator
372 Phase 2|Phase 3 RPH-104 80 mg, Olokizumab 64 mg; vs. Placebo
Proportion of patients, responded to the study 
therapy, in each of the treatment groups
Recruiting
12 NCT04479358 Randomized, open label 332 Phase 2  Tocilizumab vs. Standard of Care




13 NCT04345445 Randomized, open label 310 Phase 3 Tocilizumab,  Methylprednisolone




14 NCT04435717 Randomized, open label 78 Phase 2
Tocilizumab 20 MG/ML Intravenous Solution;
Drug: Tocilizumab 20 MG/ML Intravenous Solution (2 doses)
Change in IL-12 values in the 3 study groups 
from the start of treatment (Day 0) and on days 
1 and 3
Recruiting
15 NCT04377750 Randomized, open label 500 Phase 4 Tocilizumab Survival Recruiting
16 NCT04332094 Randomized, open label 276 Phase 2 Tocilizumab, Hydroxychloroquine, Azithromycin In-hospital mortality Recruiting
17 NCT04377659 Randomized, open label 40 Phase 2 Tocilizumab Progression of respiratory failure or death Recruiting
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18 NCT04412291 Randomized, open label 120 Phase 2
Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe vs. 
Standard-of-care treatment
Time to recovery and Mortality Recruiting
19 NCT04346355 Randomized, open label 126 Phase 2 Tocilizumab
Entry into Intensive Care with invasive 
mechanical ventilation or death from any cause 
or clinical aggravation
Terminated
20 NCT04377503 Randomized, open label 40 Phase 2
Tocilizumab 180 MG/ML, Methylprednisolone Sodium 
Succinate




21 NCT04363736 Randomized, open label 100 Phase 2 Tociliuzumab
Serum Concentration of interleukin-6 (IL-6) 
Following Administration of 8 mg/kg IV TCZ
Completed
22 NCT04361032 Randomized, open label 260 Phase 3 Tocilizumab Injection, Deferoxamine Mortality rate
Not yet 
recruiting
23 NCT04424056 Randomized, open label 216 Phase 3 Anakinra, Ruxolitinib vs. Standard of care Ventilation free days at day 28
Not yet 
recruiting
24 NCT04403685 Randomized, open label 129 Phase 3 Tocilizumab
Evaluation of clinical status and All-cause 
mortality
Terminated
25 NCT04335305 Randomized, open label 24 Phase 2 Tocilizumab, Pembrolizumab (MK-3475)
Percentage of patients with normalization of 
SpO2 on room air (measured without any 
respiratory support for at least 15 minutes) and 
Proportion of patients discharged from the 
emergency department and classified as low risk
Recruiting
26 NCT04333914 Randomized, open label 384 Phase 2
Chloroquine analog (GNS651),  Nivolumab,  Tocilizumab, 
Standard of care, Avdoralimab,  Monalizumab
28-day survival rate and Time to clinical 
improvement
Suspended
27 NCT04476979 Randomized, open label 120 Phase 2 Tocilizumab, Dexamethasone
Survival without needs of ventilator utilization 
at day 14 and WHO progression scale at day 7 
and 14
Recruiting
28 NCT04361552 Randomized, open label 0 Phase 3 Best Practice,  Tocilizumab
7-day length of invasive mechanical ventilation 
(MV)
Withdrawn
29 NCT04330638 Randomized, open label 342 Phase 3 Usual Care, Anakinra, Siltuximab, Tocilizumab Time to Clinical Improvement| Recruiting
30 NCT04331808 Randomized, open label 228 Phase 2 Tocilizumab
Survival without needs of ventilator utilization at 
day 14. Group 1
Active, not 
recruiting
31 NCT04322773 Randomized, open label 200 Phase 2 RoActemra IV vs. Standard medical care
Time to independence from supplementary 
oxygen therapy
Recruiting
32 NCT04381936 Randomized, open label 15000 Phase 2|Phase 3
Lopinavir-Ritonavir, Corticosteroid,  Hydroxychloroquine, 
Azithromycin, Convalescent plasma,  Tocilizumab, 
Immunoglobulin
All-cause mortality and Duration of hospital stay Recruiting
33 NCT04536363 Randomized, open label 284 Phase 2 Analogs, Prostaglandin vs. Standard therapeutic protocol Mortality and Hypoxemia Resolution
Not yet 
recruiting
34 NCT04359095 Randomized, open label 1600 Phase 2|Phase 3
Hydroxychloroquine|Drug, Lopinavir / Ritonavir Pill, 
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35 NCT02735707 Randomized, open label 7100 Phase 4
Fixed-duration Hydrocortisone, Shock-dependent 
hydrocortisone, Ceftriaxone, Moxifloxacin or Levofloxacin, 
Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, 
Macrolide administered for 3-5 days or 14 days, 5/10-days 
oseltamivir, Lopinavir/ritonavir, Hydroxychloroquine 
Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-
1a Anakinra, Fixed-duration higher dose Hydrocortisone, 
Tocilizumab, Sarilumab, Vitamin C,  Therapeutic 
anticoagulation, Simvastatin,  Convalescent plasm,
Protocolised mechanical ventilation strategy
All-cause mortality Recruiting
36 NCT04374539 Randomized, open label 116 Phase 2 Plasma exchange vs. Standard medical treatment Impact of plasma exchange Recruiting
37 NCT04366245 Randomized, open label 72 Phase 1|Phase 2
Hyperimmune plasma vs Standard of care for SARS-CoV-2 
infection
Safety: Incidence of Adverse Events and 
Serious Adverse Events grade 3 and 4, related 
to the product under investigation or the 
administration procedure, graduated according 
to the common toxicity criteria scale (CTCAE)
Recruiting
38 NCT04346693 Randomized, open label 320 Phase 3
Standard therapy recommended by the Ministry of Health of 
the Russian Federation and Dalargin intramuscular injection




39 NCT04401410 Randomized, open label 58 Phase 1
Dose Finding Phase (MTD), Partially HLA-matched SARS-
CoVSTs, Routine care 




40 NCT04392414 Randomized, open label 60 Phase 2
COVID-19 convalescent hyperimmune plasma,  Non-
convalescent fresh frozen plasma (Standard plasma)
30-day mortality rate Recruiting
41 NCT04414631 Randomized, open label 120 Phase 2 Conestat alfa





masking among participant, 
care provider, investigator, 
and outcomes assessor
100 Phase 2 Tocilizumab, Placebo
Number of patients with ICU admission, 





500 Phase 2|Phase 3
Hydroxychloroquine, Azithromycin/ Doxycycline/ 
Clindamycin/ Primaquine - low dose, Clindamycin,
Primaquine - high dose, Remdesivir, Tocilizumab, 
Methylprednisolone, Interferon-Alpha2B, Losartan, 
Convalescent Serum
Improvement in FMTVDM Measurement with 




44 NCT04445272 Single group, open label 500 Phase 2 Tocilizumab Mortality rate and metrics of respiratory function Recruiting
45 NCT04317092 Single Group, open label 400 Phase 2 Tocilizumab Injection One-month mortality rate Recruiting
46 NCT04363853 Single Group, open label 200 Phase 2 Tocilizumab Hematic biometry and Blood chemistry Recruiting
47 NCT04370834 Single group, open label 217 Phase 2 Tocilizumab
Clinical outcome as evaluated by the 7-category 
Clinical Status Ordinal Scale
Suspended
48 NCT04315480 Single group, open label 38 Phase 2 Tocilizumab




49 NCT04386239 Single Group, open label 40 Early Phase 1 Sarilumab Prefilled Syringe
Proportion of patients who show an 
improvement of the respiratory function
Not yet 
recruiting
50 NCT04335123 Single Group, open label 50 Phase 1 Losartan
Number of participants with treatment-related 
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investigator) studies, 30(60%) randomized, open-
label studies, 1(2%) randomized, quadruple masking 
(participant, care provider, investigator, outcomes assessor) 
study, 1(2%) randomized, single masking (investigator) 
study, and 7(14%) single group, open-label studies (Table). 
4. Discussion
To the best of our knowledge, this is the first review 
that meta-analyses the benefits of tocilizumab in severe 
COVID-19 patients along with reviewing methodologies 
of ongoing clinical trials. Our findings must be read with 
caution due to the lack of strong evidence from randomized 
controlled trials. Tocilizumab is the humanized anti-
IL-6 receptor monoclonal antibody that is approved 
specifically for cytokine release syndrome, systematic 
juvenile idiopathic arthritis, and rheumatic arthritis [18]. 
The results indicate that tocilizumab improves mortality 
outcomes in severely infected COVID-19 patients; 
however, the results do not elucidate clear demarcation 
of risks of mechanical ventilation between treatment and 
control groups.
The National Institute of Health published Interim 
guidelines suggesting that tocilizumab may be considered 
for COVID-19 patients meeting the following six criteria, 
who are otherwise ineligible for steroid therapy [19]. The 
patient 1) must be COVID-19 positive, 2) must have 
abnormal chest imaging as seen in coronavirus infections, 
worsening respiratory status over 1–2 days necessitating 
4–6 L/min of oxygen, 3) must not have any systemic 
fungal or bacterial co-infection, 4) must be suspected 
for cytokine release syndrome support by an elevation 
of inflammatory markers (for example, D-dimer > 1 
mg/L, Ferritin > 600 ug/mL, LDH > 250U/L), along with 
clinical decline, 5) must not have had a poor prognosis 
indicating an unlikely survival of over 48 h, and 6) must 
have received mechanical ventilation for 24 h or less. 
Of the studies included in the meta-analysis, Somers 
et al. only tested the benefits of tocilizumab on severe 
COVID-19 patients obtaining mechanical ventilation. 
The duration of mechanical ventilation among the 
tocilizumab and control group was 13.8d (IQR: 7.1d, 
27.5d) and 13d (IQR: 8.1d, 23.5d), respectively [12]. 
It is noted that the benefits of tocilizumab therapy on 
patients who have been mechanically ventilated patients 
for over 24 h may be low due to low chances of clinical 
improvement.2 
However, 56% of patients (n = 76) in the treatment 
group were discharged alive by the end of follow-up 
process as compared to 30% of patients (n = 76) in the 
control group suggesting that the clinical benefits must be 
assessed in the ongoing placebo-controlled trials. In the 
2 Centers for Disease Control and Prevention (2020). Information for Clinicians on Investigational Therapeutics for Patients with COVID-19 [on-
line]. Website https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html [accessed 20 September 2020].
COVACTA trial, where 452 severe COVID-19 patients 
were randomized, improvements in clinical status at day 
28 and mortality outcomes were not observed [20]. Both 
the safety and efficacy of tocilizumab must be assessed for 
patients with severe disease in the several randomized, 
double-blind, placebo-controlled phase 3 trials namely 
COVACTA, REMDACTA, and EMPACTA to corroborate 
the true benefits of the drug in acute care settings.
Our meta-analytical findings have limitations. Most of 
the included studies were retrospective cohorts; however, 
updated preprints of placebo-controlled trials solidified 
our findings. There was a lack of diagnostic criteria 
for severe COVID-19 between all studies that led to a 
difference in mechanical ventilation outcomes between 
the treatment and control groups. The inflammatory 
markers reduced ventilatory support requirements, and 
radiological improvement signs were not always presented 
in the included studies.
5. Recommendations 
All placebo-controlled trials must ascertain the optimal 
dosage of tocilizumab and the potential utility of multiple 
dosages. IL-6 serum concentration tests must be made 
routinely available when tocilizumab response is to be 
assessed [12]. Drug administration in the acute care 
setting ought to be guided by strict institutional criteria, 
thus being completely standardized. In addition to the 
regular follow up period of 28 days, the full course of 
hospitalization ought to be determined to characterize 
long-term sequelae in treatment and control groups.  
6. Conclusion 
Anti-IL-6 drugs for COVID-19 are a cause of contention 
since the outbreak of the global pandemic. Tocilizumab, 
which has had mixed results in RCTs, is being utilized 
off-label and as an experimental therapy for patients 
with COVID-19 who are sick or deteriorating with a 
slight chance of recovery. The ongoing pandemic has 
created ethical challenges concerning the nonapproved 
use among patients and choosing the most appropriate 
patient to receive the experimental therapy in the setting 
of ongoing randomized controlled trials [21]. The review 
attempted to link the key tocilizumab studies, find benefits 
in case of mortality and the risk of mechanical ventilation 
by the end of treatment, to steer the narrative for ongoing 
registered trials, which will ultimately form the fate for the 
use of tocilizumab in COVID-19. 
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